Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
5,019 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J, Chan KE, Wong ZY, et al. · Lancet Gastroenterol Hepatol · 2023Meta-Analysis, Systematic Review
- Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
Wang Y, Zhou Y, Wang Z, et al. · J Clin Endocrinol Metab · 2025Systematic Review, Meta-Analysis
- Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
En Li Cho E, Ang CZ, Quek J, et al. · Gut · 2023Meta-Analysis, Systematic Review
- Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Ye Q, Zou B, Yeo YH, et al. · Lancet Gastroenterol Hepatol · 2020Meta-Analysis, Systematic Review
- The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
Younossi ZM, Golabi P, Price JK, et al. · Clin Gastroenterol Hepatol · 2024Meta-Analysis
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ, Gaunt P, Aithal GP, et al. · Lancet · 2016Clinical Trial, Phase II, Multicenter Study
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Dulai PS, Singh S, Patel J, et al. · Hepatology · 2017Meta-Analysis, Systematic Review
- The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM, Golabi P, de Avila L, et al. · J Hepatol · 2019Meta-Analysis, Research Support, Non-U.S. Gov't
- Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Bandyopadhyay S, Das S, Samajdar SS, et al. · Diabetes Metab Syndr · 2023Meta-Analysis, Systematic Review
- Nonalcoholic fatty liver disease: a systematic review.
Rinella ME · JAMA · 2015Systematic Review
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Le MH, Le DM, Baez TC, et al. · Clin Mol Hepatol · 2024Meta-Analysis, Systematic Review
- Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis.
Chai SY, Zhang RY, Fernandes G, et al. · World J Gastroenterol · 2025Systematic Review, Meta-Analysis
- Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Singh S, Allen AM, Wang Z, et al. · Clin Gastroenterol Hepatol · 2015Comparative Study, Meta-Analysis
- Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis.
Lee EJ, Choi M, Ahn SB, et al. · World J Pediatr · 2024Systematic Review, Meta-Analysis
- Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials.
Arita VA, Cabezas MC, Hernández Vargas JA, et al. · BMC Med · 2025Meta-Analysis, Systematic Review
- Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, Chalasani N, Kowdley KV, et al. · N Engl J Med · 2010Clinical Trial, Phase III, Comparative Study
- Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
Mantovani A, Petracca G, Beatrice G, et al. · Gut · 2022Meta-Analysis, Research Support, Non-U.S. Gov't
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA, Mózes FE, Jayaswal ANA, et al. · J Hepatol · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS, Taylor RJ, Bayliss S, et al. · Gastroenterology · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.
Suvarna R, Shetty S, Pappachan JM · Sci Rep · 2024Systematic Review, Meta-Analysis
- Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study.
Song Y, Ni W, Zheng M, et al. · Cell Rep Med · 2025Multicenter Study, Randomized Controlled Trial
- Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials.
Mantovani A, Morandin R, Fiorio V, et al. · Liver Int · 2025Meta-Analysis, Systematic Review
- Efficacy of the Mediterranean Diet Containing Different Macronutrients on Non-Alcoholic Fatty Liver Disease.
Uluçay Kestane V, Baş M · Nutrients · 2024Randomized Controlled Trial
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K, Orsak B, Bril F, et al. · Ann Intern Med · 2016Randomized Controlled Trial
- Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis.
Hwang J, Hwang H, Shin H, et al. · Clin Mol Hepatol · 2024Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.